Today, the FDA approved telapravir for Hep C. That’s happy news at Vertex (and Merck last week) but an all-too-rare story of new drugs meeting significant human health needs.
More like this, please.
The Incidental Economist
the health services research blog
Boston-area website management by BKJ Productions